MAGE-G2 Activators
MAGE-G2, primarily associated with the negative regulation of transcription by RNA polymerase II and active in the nucleus, is influenced by a spectrum of chemical compounds that modulate chromatin structure and DNA methylation patterns. Histone deacetylase inhibitors like Trichostatin A, Vorinostat, Valproic Acid, Romidepsin, Panobinostat, Entinostat, and Sodium Butyrate play a pivotal role in enhancing MAGE-G2's functional activity. These compounds induce chromatin relaxation by altering histone acetylation levels, thereby facilitating easier access of MAGE-G2 to its target DNA regions. This relaxed chromatin state is crucial for MAGE-G2 to exert its regulatory effects more efficiently. Similarly, Sirtinol, by inhibiting sirtuin deacetylases, contributes to this chromatin remodeling, further aiding MAGE-G2's ability to access and regulate transcription. The influence of these compounds is not limited to chromatin structure modification but extends to the alteration of DNA methylation patterns.
DNA methyltransferase inhibitors like 5-Azacytidine, RG108, and Decitabine play a significant role in the activation of MAGE-G2. By reducing the methylation levels of DNA, these compounds unveil MAGE-G2's target sites, thereby augmenting its capacity to regulate transcription. Mithramycin A, though primarily a DNA-binding drug, contributes indirectly by potentially altering the chromatin landscape, which could further facilitate MAGE-G2's interaction with its genomic targets. The concerted action of these chemical activators, through their targeted effects on chromatin structure and DNA methylation, collectively enhances the functional activity of MAGE-G2. This enhancement is crucial for MAGE-G2 to effectively fulfill its role in the negative regulation of transcription, pivotal for numerous cellular processes within the nucleus.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, enhances MAGE-G2 function by promoting chromatin relaxation. This relaxed state of chromatin allows easier access for MAGE-G2 to its target sites on DNA, facilitating its role in the negative regulation of transcription by RNA polymerase II. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, indirectly enhances MAGE-G2 activity by reducing DNA methylation levels. This demethylation can lead to the exposure of MAGE-G2 target sites on DNA, enhancing its ability to negatively regulate transcription. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another histone deacetylase inhibitor, functions similarly to Trichostatin A by relaxing chromatin structure, thus enhancing the accessibility of MAGE-G2 to its target DNA regions, and facilitating its regulatory role in transcription. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid, also a histone deacetylase inhibitor, boosts MAGE-G2 activity by promoting chromatin decondensation. This makes the DNA more accessible for MAGE-G2, aiding in its function of transcriptional regulation. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A, a DNA-binding drug, indirectly influences MAGE-G2 activity. It binds to GC-rich DNA sequences and may alter the chromatin landscape, potentially enhancing MAGE-G2’s ability to access and regulate its target genes. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108, a non-nucleoside DNA methyltransferase inhibitor, enhances MAGE-G2 activity by reducing DNA methylation. This decrease in methylation can improve MAGE-G2’s access to DNA, thus aiding its role in transcriptional regulation. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin, a histone deacetylase inhibitor, functions similarly to Vorinostat and Trichostatin A, facilitating chromatin relaxation. This enhances MAGE-G2's access to its regulatory sites, improving its ability to regulate transcription. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat, another histone deacetylase inhibitor, boosts MAGE-G2 activity by promoting chromatin openness, aiding MAGE-G2 in accessing its target DNA regions and thus enhancing its transcriptional regulatory function. | ||||||
Sirtinol | 410536-97-9 | sc-205976 sc-205976A | 1 mg 5 mg | $38.00 $113.00 | 14 | |
Sirtinol, an inhibitor of SIRT1 and SIRT2 (sirtuin deacetylases), may indirectly enhance MAGE-G2 activity. By altering the histone acetylation landscape, Sirtinol could facilitate greater access for MAGE-G2 to its target DNA regions. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine, a DNA methyltransferase inhibitor, enhances MAGE-G2 activity by reducing overall DNA methylation levels, which could lead to an increased accessibility of MAGE-G2 to its target sites on DNA, aiding its regulatory role. | ||||||